免疫介导疾病的双重生物治疗:一个单一的中心体验
Oded Shamriz1,2, Elchanan Parnasa3, Limor Rubin4
1Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. oded.shamriz@mail.huji.ac.il.
BMC immunology
|April 8, 2025
概括
结合奥马利祖马布和其他单克隆抗体的双重生物疗法对于管理Th2和非Th2疾病是安全有效的. 这种方法在慢性自发性疹和喘患者中显示出没有不良事件的临床改善.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 医生经常面临临临床情景,需要将奥马利祖马布与非IgE向单克隆抗体联合使用.
- 了解这种双重生物治疗的安全性和疗效对于优化患者护理至关重要.
- 本研究介绍了这些联合治疗策略的初步经验.
研究的目的:
- 评估双重生物疗法的疗效和安全性,包括奥马利祖马布和非IgE向单克隆抗体.
- 评估在一个中心接受这种联合治疗方案的患者的临床结果和不良事件.
主要方法:
- 对2020年至2022年期间接受双重生物疗法治疗的成年患者医疗记录的回顾性审查.
- 治疗方案包括将奥马利祖马布与另一种生物药物结合.
- 患者有高的Th2疾病,如慢性自发性疹和喘.
主要成果:
- 九名患者 (51-75岁) 接受了针对Th2介导疾病 (慢性自发性疹,喘) 的双重生物疗法.
- 使用了各种非IgE向生物药物,包括抗IL-5,IL-4/13,IL-17,IL-1,抗CGRP和抗TNF-α药物.
- 进行3至34个月的双重生物治疗,导致临床改善,没有报告的不良事件或感染.
结论:
- 结合奥马利祖马布和其他生物药物的双重生物治疗似乎是安全有效的.
- 非IgE向剂可以安全地与奥马利祖马布联合使用.
- 这种治疗策略对管理复杂的过敏和炎症状况充满希望.
相关概念视频
Cell-mediated Immune Responses
64.7K
Overview
64.7K
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cytotoxic T Cells-mediated Immune Response
7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K


